Caregen to release US phase 1 results for eyedrop CG-P5 against Eylea Caregen to reveal delayed phase 1 eyedrop data for ...
Conexeu Sciences Inc. ("Conexeu" or the "Company"), a biotechnology innovator redefining regenerative medicine through a next ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback